Fianlimab
As of the edition of 20 October 2026, Fianlimab is an antibody: in active development; acts on LAG3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2030
- Kind
- Antibody
- Registered trials
- 39, 3 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Digestive system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LAG3 | Lymphocyte activation gene 3 protein | P18627 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 4 | 1 | 2 | 1 |
| Phase 2 | 29 | 0 | 26 | 2 |
| Phase 3 | 5 | 0 | 5 | 0 |
| All trials | 39 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Regeneron | Lead sponsor of trials | 2016 to now |